Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria
Condition: Porphyrias Intervention: Other: Web-based Survey Sponsors: University of South Florida; University of Texas; Wake Forest University Health Sciences; University of Miami; University of Washington; Icahn School of Medicine at Mount Sinai; University of Alabama at Birmingham; University of California, San Fra ncisco; University of Utah; National Institutes of Health (NIH) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2019 Category: Research Source Type: clinical trials
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2019-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2019 Category: Pharmaceuticals Source Type: clinical trials
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 21, 2018 Category: Pharmaceuticals Source Type: clinical trials
